NEW YORK, February 21, 2013 /PRNewswire/ --
Today, National Traders Association announced new research
reports highlighting Novogen Limited (NASDAQ: NVGN), Sanofi SA
(NYSE: SNY), ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS), Amgen, Inc.
(NASDAQ: AMGN) and Gilead Sciences, Inc. (NASDAQ: GILD). Today's
readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the
links below.
Novogen Limited Research Report
Novogen's shares jumped 200 percent after a study revealed that
its anti-ovarian cancer drug was not only effective against ovarian
cancer cells, it was also effective against ovarian cancer stem
cells. Cancer stem cells have been found in a range of cancers
including ovarian, brain and leukemia, and are resistant to
radiotherapy and typical anti-cancer drugs. They are also normally
responsible for cancer recurrence, the main cause of death among
patients. With this new discovery, Novogen hopes that its new drug,
the CS-6 and the super benzopyran family of drugs to which it
belongs, would eventually become a comprehensive cancer treatment.
Many investors have already jumped to buy shares, expecting that
CS-6 would become the catalyst for Novogen's long-term growth. The
Full Research Report on Novogen Limited - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/0f8c_NVGN]
--
Sanofi SA Research Report
Sanofi's shares rallied after the U.S. Food and Drug
Administration (FDA) accepted lixisenatide for review. Lixisenatide
is the first once-daily treatment of adults with type 2 diabetes
mellitus. Lixisenatide has also been approved for the European
Union, and will be launched as Lyxumia later in the first quarter.
This follows regulatory approvals for Kynamro, Zaltrap, and
Aubagio. Additionally, Sanofi's subsidiary Genzyme also announced
positive new data from phase 3 ENGAGE and ENCORE studies of
eliglustat tartrate, an investigational oral therapy for Gaucher
disease type 1. With a string of approvals to boast of, many
believe that the pharmaceutical giant will be able to generate
strong revenue in the upcoming quarters. Warren Buffett is
among Sanofi's shareholders, along with Abrams Capital. The Full
Research Report on Sanofi SA - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/63b2_SNY]
--
ISIS Pharmaceuticals, Inc. Research
Report
ISIS and Genzyme have announced the US Food and Drug
Administration (FDA) approval of their new product, the KYNAMROTM
injection. The injection reduces low density
liproprotein-cholesterol, apoliprotein B, total cholesterol, and
high density lipoprotein-cholesterol in patients with homozygous
familial hypercholesterolemia (HoFH). HoFH is a rare inherited
condition which makes the body unable to remove LDL cholesterol. In
the United States, HoFH occurs in
one in a million individuals, and for patients with this condition,
heart attacks, and death can occur before age 30. Analysts expect
that the product will earn $400
million in peak sales, with Isis getting 30 percent to 50
percent of the profit, depending on total sales. Sanofi, the pharma
giant that owns Genzyme, will be helping to market this product.
Moreover, ISIS recently earned $7.5
million payment from GlaxoSmithKline for the initiation of
the Phase2/3 clinical study of ISIS-TTR, a treatment for
transthyretin (TTR) amyloidosis, a genetic disease characterized by
the dysfunction of peripheral nerve or heart tissues. The Full
Research Report on ISIS Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/555f_ISIS]
--
Amgen, Inc. Research Report
Amgen reported that its late-stage pipeline is advancing, with
two pivotal phase 3 trials due this year, five in 2014, and one in
2016. Analysts have been praising Amgen for its promising pipeline
and its solid long-term strategy, with researchers at the Jefferies
Group reiterating their buy rating on the shares of the company.
The world's largest biotechnology company notes six biosimilars as
its next opportunity for growth, hoping that these products would
generate a combined peak of $41
billion in global sales. It is also creating a new
manufacturing process that includes launching new manufacturing
technologies that aim to reduce the capital needed to produce
products. It is also planning to expand globally as it launches
products in Japan by 2016. The
Full Research Report on Amgen, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/7b3e_AMGN]
--
Gilead Sciences, Inc. Research
Report
Gilead announced results from the Phase 3 FUSION study of its
Hepatitis C drug, Sofosbuvir. The study concluded that the drug is
effective in treating Hepatitis C patients who could not be cured
by existing medications that contained pegylated interferon.
Interferon is an ingredient loaded with side effects that often led
to patients discontinuing therapy. With this, Gilead is on track to
file regulatory applications for the drug in the United States and Europe in the second quarter. The results mark
a remarkable run for the company after taking less than 16 months
to finish its Phase III phase. The Full Research Report on Gilead
Sciences, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.NationalTradersAssociation.org/r/full_research_report/6e69_GILD]
--
Consider National Traders Association
Tired of hearing about the latest, greatest trade opportunity...
only to realize that the ship has long sailed? You need a strong,
informative community in your arsenal. Join the group that has been
consistently identifying momentous situations as they develop -
long before they become the next top news on major financial
networks.
Contact: Demi Lapierre
Email: press@NationalTradersAssociation.org
Main: +1(702)212-4493
SOURCE National Traders Association